PATENT CLAIM ANALYSIS

Application Number: 15747642
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "450000"]

Abstract:
A method for the targeted delivery of the active generic antiproliferative and anti-inflammatory agents gemcitabine, paclitaxel and/or curcumin preferentially or exclusively to antigen-presenting cells (APCs) of the immune system by means of encapsulation into a lipid-based nanocarrier, the CLR-TargoSphere, which is surface-labeled with a Fucose-derivative ligand that exclusively targets C-type lectin receptors (CLRs) on APCs to deliver the active agents intracellularly to myeloid dendritic cells (mDCs), circulating monocytes, macrophages, and tumor-associated macrophages (TAMs) as well as cytotoxic T lymphocytes (CTLs).

Claim (Index 19):
The nanocarrier for the use of  claim 11 , wherein the combination of different permutations of the nanocarriers loaded with different pharmaceutical agents is to achieve an optimal therapeutic effect that is superior to the outcome that can be achieved with the non-encapsulated agents or the same pharmaceutical agents when encapsulated in non-targeted nanocarriers.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 86.0
- Lexical Diversity: 1.44776
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11221179', '15460701', '13279766', '14233527', '14959497']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7122964125800217
- 35 USC 102 Novelty (BERT): 0.4985459164384042
- Combined Prediction Score: 0.69092136296586
- Mean Citation Score: 192.755482
- Max Citation Score: 194.39374
- Similarity Product: 123.04412629493235

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test